"Platinum resistant" ovarian cancer: What is it, who to treat and how to measure benefit?
"Platinum resistant" ovarian cancer was historically defined as disease recurrence within 6 months of completion of first-line platinum-based chemotherapy, although this is now more broadly applied to also include patients progressing within 6 months after multiple lines of chemotherapy. However, this definition ignores the heterogeneity and complexity of the spectrum of diseases that comprise "platinum resistant ovarian cancer" (PROC) and is innately flawed as it was initially derived using...[Show more]
|Collections||ANU Research Publications|
|01_Davis_"Platinum_resistant"_ovarian_2014.pdf||318.68 kB||Adobe PDF||Request a copy|
Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.